Soleno Therapeutics - Public Comps and Valuation Multiples

Soleno Therapeutics Overview

About Soleno Therapeutics

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

Founded

1999

HQ

Employees

Website

soleno.life

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $115M

Last FY EBITDA -$174M

EV

$3.2B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Soleno Therapeutics Financials

As of September 2025, Soleno Therapeutics reported last 12-month revenue of $115M.

In the same period, Soleno Therapeutics generated $108M in LTM gross profit and -$61.7M in net income.

See Soleno Therapeutics valuation multiples based on analyst estimates

Soleno Therapeutics P&L

In the most recent fiscal year, Soleno Therapeutics reported EBITDA of -$174M.

Soleno Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Soleno Therapeutics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$115M	XXX	n/a	XXX	XXX	XXX
Gross Profit	$108M	XXX	n/a	XXX	XXX	XXX
Gross Margin	94%	XXX	n/a	XXX	XXX	XXX
EBITDA	n/a	XXX	-$174M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBIT	-$67.8M	XXX	-$184M	XXX	XXX	XXX
EBIT Margin	-59%	XXX	n/a	XXX	XXX	XXX
Net Profit	-$61.7M	XXX	-$176M	XXX	XXX	XXX
Net Margin	-54%	XXX	n/a	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Soleno Therapeutics including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $115M.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$115M	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$108M	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	93.9% gross margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	-$174M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$67.8M	Analyst estimates available to subscribers	-$184M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-59.1% EBIT margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$61.7M	Analyst estimates available to subscribers	-$176M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-53.7% net profit margin	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Soleno Therapeutics

This financial data table provides comprehensive performance metrics for Soleno Therapeutics, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Soleno Therapeutics generated $115M in revenue over the last twelve months.
Gross profit for the last twelve months was $108M.
Net income over the last twelve months reached -$61.7M.

Fiscal Year Performance

Fiscal year EBITDA was -$174M.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Soleno Therapeutics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Soleno Therapeutics Stock Performance

Soleno Therapeutics has current market cap of $3.5B, and EV of $3.2B.

Market Cap Evolution

Soleno Therapeutics Stock Data

As of October 17, 2025, Soleno Therapeutics's stock price is $65.

See Soleno Therapeutics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.2B	$3.5B	XXX	XXX	XXX	XXX	$-1.41

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Soleno Therapeutics Valuation Multiples

Soleno Therapeutics's trades at n/a EV/Revenue multiple, and -18.7x EV/EBITDA.

See valuation multiples for Soleno Therapeutics and 15K+ public comps

Soleno Therapeutics Financial Valuation Multiples

As of October 17, 2025, Soleno Therapeutics has market cap of $3.5B and EV of $3.2B.

Equity research analysts estimate Soleno Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Soleno Therapeutics has a P/E ratio of -56.4x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$3.5B	XXX	$3.5B	XXX	XXX	XXX
EV (current)	$3.2B	XXX	$3.2B	XXX	XXX	XXX
EV/Revenue	28.3x	XXX	n/a	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-18.7x	XXX	XXX	XXX
EV/EBIT	-47.8x	XXX	-17.6x	XXX	XXX	XXX
EV/Gross Profit	30.1x	XXX	n/a	XXX	XXX	XXX
P/E	-56.4x	XXX	-19.8x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-46.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Soleno Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Soleno Therapeutics Margins & Growth Rates

Soleno Therapeutics's last 12 month revenue growth is 206%

Soleno Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $2.0M for the same period.

Soleno Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Soleno Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Soleno Therapeutics and other 15K+ public comps

Soleno Therapeutics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	206%	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$2.0M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial